Praxisrelevanz der Genetik in der Gynäkologischen Onkologie (S. 9–20)
B. Ataseven, N. Pauly, A. du Bois


17. Rhiem K et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res 2012; 14: R156
37. Moran A et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 2012; 11: 235–42
38. https://www.konsortium-familiaerer-brustkrebs.de/konsensusempfehlung/

40. ASK2ME. https://ask2me.org/


44. Fasching PA et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018; 36: 2281–87


64. PEREMM5. https://premm.dfci.harvard.edu/


---

**Die Therapie des epithelialen Ovarialkarzinoms (S. 21–31)**

*N. Pauly, A. du Bois, B. Ataseven*


20. Banerjee S et al. 811MO: Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Ann Oncol 2020; 31: S613
24. Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol 2018; 80: 11–27
28. Ledermann JA et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial. Gynecol Oncol2020; 159: 13–14
29. Roche. Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer. In; 2020
31. Harter P et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011; 21: 289–95


40. Colombo N et al. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6–12 months after last platinum line. Ann Oncol 2020; 31: S1161


57. Marme F et al. AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). J Clin Oncol 2019; 37(15)suppl, abstr. # TPS5601

58. González-Martín A et al. ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp)> 6 months. J Clin Oncol 2019; 37(15)suppl, abstr. # TPS5599


Mammakarzinom und Schwangerschaft – Empfehlungen für Klinik und Praxis (S. 39–44)
S. Seiler, S. Loibl


27. Calsteren KV et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer 2010; 20(9): 1456–64


33. Fachinformation Herceptin®, Stand März 2021


Komplementärmedizin in der Gynäkologischen Onkologie – Resilienz und Insomnie (S. 50–58)
P. Klose, A. Paul, G. Dobos, S. Kümml, P. Voß


4. SIO. https://integrativeonc.org/. Letzter Aufruf: 18.03.2021

5. PRIO. https://prio-dkg.de/. Letzter Aufruf: 18.03.2021


33. Bach L, Kalder M, Kostev K. Depression and sleep disorders are associated with early mortality in women with breast cancer in the United Kingdom. J Psychiatr Res 2020; S0022-3956(20)31096-7
45. Troger W et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. Breast Cancer (Auckl) 2009; 3: 35–45
47. Yang HL et al. The effects of warm-water footbath on relieving fatigue and insomnia of the gynecologic cancer patients on chemotherapy. Cancer Nurs 2010; 33: 454–60